Clinical trials: HIV Infection, completed
Human Papilloma Virus, HIV Infections
ERADICATING CERVICAL CANCER IN KENYA
This is a study of a strategy designed to 1) increase cervical cancer screening using a community-based approach, and 2) determine the efficacy of HPV vaccination in a region of Kenya where half of all children are chronically…
- Trial name
- NCT04774887
- Testing
- HPV vaccine, Merck
- Where
- Kenya
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV Infections
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral therapy in developing countries. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could…
- Trial name
- NCT02945163
- Testing
- Tenofovir, Lamivudine, Efavirenz
- Where
- 3 sites in China
- Volunteers
- 184 people
- Sponsor
- Shanghai Public Health Clinical Center
Acquired Immunodeficiency Syndrome, Anemia
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
To determine whether administration of human recombinant erythropoietin (REPO) improved or eliminated the anemia seen in human immunodeficiency virus (HIV) infected patients after therapy with zidovudine (ZDV).
- Conditions
- Acquired Immunodeficiency Syndrome, Anemia, Hematologic Diseases, HIV Infections
- Trial name
- NCT00000587
- Testing
- erythropoietin, recombinant
- Sponsor
- Thomas Jefferson University
HIV Infection
Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients
This study evaluates the impact of highly active antiretroviral therapy on the size of the latent viral reservoirs in resting CD4+ T cells and monocytes in HIV positive patients.
- Trial name
- EURECA (NCT02858414)
- Testing
- additional blood sample
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
HIV Infections
Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients
This pilot study focuses on the persistence of central nervous system (CNS) immune activation that has been observed in the presence of 'effective' combination antiretroviral therapy (cART).
- Trial name
- NCT00672932
- Testing
- raltegravir
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Candidiasis, Esophageal, HIV Infections
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.
- Trial name
- NCT00002132
- Testing
- Itraconazole, Fluconazole
- Where
- 18 sites in United States
- Sponsor
- Janssen Pharmaceuticals
HIV Infections
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
- Trial name
- NCT00002416
- Testing
- Emtricitabine, Lamivudine
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Triangle Pharmaceuticals
Pneumonia, Pneumocystis Carinii, HIV Infections
Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis
To determine whether gradual initiation of sulfamethoxazole/trimethoprim (SMX/TMP) reduces the incidence of treatment-limiting adverse reactions compared to the routine initiation of the drugs for Pneumocystis carinii pneumonia…
- Trial name
- NCT00000816
- Testing
- Sulfamethoxazole-Trimethoprim
- Where
- 42 sites in United States, Puerto Rico and 1 more
- Volunteers
- 370 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumors
A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
Background: The PI3K/Akt/mTOR pathway is an important target in cancer because it promotes chemotherapeutic resistance and confers a poor prognosis for many types of cancers.
- Trial name
- NCT01445106
- Testing
- Nelfinavir, Nelfinavir Mesylate
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Opiate Dependence, Human Immunodeficiency Virus
Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
To address the question of the comparison of two courses of Vivitrol with differing lengths in 130 HIV negative, consenting, opioid addicted patients who have completed inpatient treatment.
- Trial name
- NCT01882361
- Testing
- injectable naltrexone
- Where
- Russia
- Volunteers
- 77 people
- Sponsor
- University of Pennsylvania
Tuberculous Pericarditis, HIV Status
High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10).
- Trial name
- IMPI-3 (NCT04521803)
- Testing
- high dose Rifampicin (RIF)
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Cape Town
HIV Risk
Rapid HIV Testing and Counseling in High Risk Women in Shelters
This is a developmental study evaluating a new rapid HIV testing and risk prevention intervention for residents of battered women's shelters who endorse risky sexual behaviors.
- Trial name
- NCT01866046
- Testing
- RESPECT-IPV
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- The University of Akron
HIV-1 Infection
Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)
The primary objectives of this study are to evaluate the antiretroviral activity and the safety/tolerability of open-label doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF; MK-1439A; DELSTRIGO™) consisting of a…
- Trial name
- DRIVE BEYOND (NCT02629822)
- Testing
- Doravirine/lamivudine/tenofovir disoproxil fumarate
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis, Oral, HIV Infections
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients…
- Trial name
- NCT00002431
- Testing
- Chlorhexidine gluconate
- Where
- 5 sites in United States
- Sponsor
- Procter and Gamble
HIV Infections
Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
The purpose of this study was to assess the safety and pharmacokinetics (PK) of three monoclonal antibodies, VRC01, VRC01LS, and VRC07-523LS, in HIV-exposed infants who are at increased risk of mother-to-child HIV transmission.
- Trial name
- NCT02256631
- Testing
- VRC01, VRC01LS, VRC07-523LS
- Where
- 14 sites in United States, Puerto Rico and 2 more
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 and Hepatitis C Co-Infection
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes.
- Trial name
- NCT00665353
- Testing
- pioglitazone, peginterferon, ribavirin
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hiv
Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)
BACKGROUND: Long-acting injectable antiretroviral therapy (LAI-ART) is poised to revolutionize HIV treatment and prevention. Community pharmacies could serve as another place for people with HIV to get their ART injections.
- Trial name
- NCT05152953
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of California, San Francisco
HIV Infections
Faster Identification of TB and Evaluation of Drug Resistance in HIV-infected People
Early identification of tuberculosis (TB) is of particular importance in HIV-infected individuals, as a delay of therapy can be devastating in those with compromised immune systems.
- Trial name
- FASTER (NCT00959088)
- Where
- 3 sites in Brazil, Peru and 1 more
- Volunteers
- 641 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV, HIV Infections
Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy
INTRODUCTION: Studies prove that the pharmaceutical care (PC) increases the adherence to the antiretroviral; thus, they increase the undetectable viral load.
- Trial name
- PC-HIV (NCT00959361)
- Testing
- pharmaceutical care
- Where
- Brazil
- Volunteers
- 332 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Hepatitis C, Hepatitis C, Chronic
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
A clinical observational study for patients with HIV co-infected with hepatitis C that investigates the levels of their health literacy, hepatitis C and HIV knowledge.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
- Trial name
- NCT03413696
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.